Penetration of roxithromycin into bronchial secretions.
The penetration of an antibacterial agent into the bronchial secretions is a crucial factor in determining its clinical efficacy in the treatment of bacterial respiratory infections. Roxithromycin is a novel macrolide compound active against the most frequent respiratory pathogens. Following administration of 150 mg p.o., we observed a prompt penetration of the compound into bronchial secretions of critically ill patients. Elevated concentrations above the MICs of the commonest susceptible pathogens are reached and maintained until the next administration.
Boccazzi
A
A
Clinica Pediatrica, Università di Milano, Italia.
Langer
M
M
D000042:Absorption; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D001980:Bronchi / Q000378:metabolism*; D002648:Child; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007362:Intensive Care Units; D007442:Intubation, Intratracheal; D008297:Male; D008875:Middle Aged; D015575:Roxithromycin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*
D015575:Roxithromycin